步长制药
(603858)
| 流通市值：168.78亿 | | | 总市值：168.78亿 |
| 流通股本：11.06亿 | | | 总股本：11.06亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 8,514,403,594.83 | 5,431,672,307.69 | 2,640,556,945.44 | 13,245,133,303.78 |
| 营业收入 | 8,514,403,594.83 | 5,431,672,307.69 | 2,640,556,945.44 | 13,245,133,303.78 |
| 二、营业总成本 | 7,978,935,292.72 | 5,064,719,032.25 | 2,473,516,485.85 | 12,225,169,654.54 |
| 营业成本 | 3,650,734,503.88 | 2,335,236,098.84 | 1,091,518,427.21 | 4,218,281,873.36 |
| 税金及附加 | 122,823,188.06 | 73,788,000.28 | 40,711,266.82 | 215,360,630.01 |
| 销售费用 | 3,271,091,901.53 | 2,068,412,415.11 | 1,062,868,990.37 | 6,368,841,921.67 |
| 管理费用 | 664,107,114.37 | 405,877,042.18 | 204,645,664.71 | 995,941,119.87 |
| 研发费用 | 180,201,501.97 | 122,027,270.5 | 46,021,307.86 | 335,081,014.06 |
| 财务费用 | 89,977,082.91 | 59,378,205.34 | 27,750,828.88 | 91,663,095.57 |
| 其中:利息费用 | 94,771,086.77 | 62,557,890.97 | 29,353,007.06 | 109,931,398.82 |
| 其中:利息收入 | 5,563,587.71 | 3,581,477.34 | 1,842,320.62 | 18,823,380.16 |
| 加:公允价值变动收益 | -779,841.27 | -2,953,441.37 | -1,957,899.34 | -2,356,116.14 |
| 加:投资收益 | 7,470,994.07 | 3,223,803.03 | -2,122,197.44 | 21,292,517.55 |
| 资产处置收益 | 23,475.93 | 33,873.75 | 1,236.95 | 1,529,515.21 |
| 资产减值损失(新) | -28,058,529.53 | -22,290,970.42 | -127,871.52 | -700,721,937.96 |
| 信用减值损失(新) | 17,920,065.2 | 28,181,428.88 | 25,954,623.03 | -17,320,669.38 |
| 其他收益 | 62,865,604.77 | 36,430,704.57 | 24,340,405.14 | 113,631,877.22 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 594,910,071.28 | 409,578,673.88 | 213,128,756.41 | 436,018,835.74 |
| 加:营业外收入 | 2,857,426.76 | 1,972,865.55 | 334,017.86 | 7,838,466.41 |
| 减:营业外支出 | 95,921,644.03 | 7,578,727 | 3,059,632.3 | 49,300,519.68 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 501,845,854.01 | 403,972,812.43 | 210,403,141.97 | 394,556,782.47 |
| 减:所得税费用 | 283,970,021.79 | 222,837,612.88 | 122,704,270.11 | 242,691,584.16 |
| 六、净利润 | 217,875,832.22 | 181,135,199.55 | 87,698,871.86 | 151,865,198.31 |
| 持续经营净利润 | 217,875,832.22 | 181,135,199.55 | 87,698,871.86 | 151,865,198.31 |
| 归属于母公司股东的净利润 | 312,863,200.9 | 231,416,651.7 | 114,015,551.69 | 318,973,324.8 |
| 少数股东损益 | -94,987,368.68 | -50,281,452.15 | -26,316,679.83 | -167,108,126.49 |
| (一)基本每股收益 | 0.29 | 0.21 | 0.1 | 0.29 |
| (二)稀释每股收益 | 0.29 | 0.21 | 0.1 | 0.29 |
| 八、其他综合收益 | -68,691.63 | -349,025.36 | -203,622.75 | -298,746.38 |
| 归属于母公司股东的其他综合收益 | -68,691.63 | -349,025.36 | -203,622.75 | -298,746.38 |
| 九、综合收益总额 | 217,807,140.59 | 180,786,174.19 | 87,495,249.11 | 151,566,451.93 |
| 归属于母公司股东的综合收益总额 | 312,794,509.27 | 231,067,626.34 | 113,811,928.94 | 318,674,578.42 |
| 归属于少数股东的综合收益总额 | -94,987,368.68 | -50,281,452.15 | -26,316,679.83 | -167,108,126.49 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |